PMID- 34670512
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20220531
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 21
IP  - 1
DP  - 2021 Oct 20
TI  - Regorafenib combined with transarterial chemoembolization for unresectable 
      hepatocellular carcinoma: a real-world study.
PG  - 393
LID - 10.1186/s12876-021-01967-3 [doi]
LID - 393
AB  - BACKGROUND: The benefits and tolerability of transarterial chemoembolization 
      (TACE) combined with regorafenib as a second-line therapy has not been reported 
      for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the 
      benefits and tolerability of TACE combined with second-line regorafenib in 
      patients with unresectable advanced HCC and failure to first-line treatment. 
      METHODS: This was a multicenter retrospective study of patients with progression 
      after first-line sorafenib and/or lenvatinib between 01/2019 and 04/2020 at four 
      tertiary hospitals in China. The patients were treated with TACE. Then, 5-7 days 
      after the first TACE, the patients started taking regorafenib for 3 weeks every 
      4-week cycle. The overall survival (OS), time to progression (TTP), 
      progression-free survival (PFS), and adverse events (AEs) were observed. RESULTS: 
      The median follow-up was 5.6 (range 0.7, 17.0) months. The median age was 60 
      (range 35, 79) years. There were 32 (84.2%) males. The patients underwent a 
      median of three TACE sessions (range 1-13). The initial doses of regorafenib were 
      20 mg/d (n = 1, 2.6%), 80 mg/d (n = 10, 26.3%), 120 mg/d (n = 15, 39.5%), and 
      160 mg/d (n = 11, 28.9%). The incidence of grade 3/4 AEs was 15.8%. Two patients 
      stopped regorafenib due to AEs. The median OS was 14.3 months. The median PFS and 
      TTP were 9.1 (95% CI 4.0, 14.2) and 9.1 (95% CI 5.5, 12.8) months, respectively. 
      CONCLUSIONS: The present study provides real-world evidence indicating that 
      regorafenib combined with TACE was beneficial and tolerable in patients with 
      unresectable HCC. Additional prospective large-scale studies are required for 
      confirmation.
CI  - (c) 2021. The Author(s).
FAU - Han, Yue
AU  - Han Y
AD  - Department of Interventional Therapy, National Cancer Center, National Clinical 
      Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China. doctorhan@163.com.
FAU - Cao, Guang
AU  - Cao G
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Interventional Therapy, Peking University 
      Cancer Hospital and Institute, Beijing, 100142, China.
FAU - Sun, Bin
AU  - Sun B
AD  - Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, 
      Capital Medical University, Beijing, 100069, China.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Interventional Radiology and Vascular Surgery, First Hospital, 
      Peking University, Beijing, 100034, China.
FAU - Yan, Dong
AU  - Yan D
AD  - Department of Interventional Therapy, National Cancer Center, National Clinical 
      Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Xu, Haifeng
AU  - Xu H
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Interventional Therapy, Peking University 
      Cancer Hospital and Institute, Beijing, 100142, China.
FAU - Shi, Qinsheng
AU  - Shi Q
AD  - Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, 
      Capital Medical University, Beijing, 100069, China.
FAU - Liu, Zechuan
AU  - Liu Z
AD  - Department of Interventional Radiology and Vascular Surgery, First Hospital, 
      Peking University, Beijing, 100034, China.
FAU - Zhi, Weihua
AU  - Zhi W
AD  - Department of Interventional Therapy, National Cancer Center, National Clinical 
      Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, 100021, China.
FAU - Xu, Liang
AU  - Xu L
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Interventional Therapy, Peking University 
      Cancer Hospital and Institute, Beijing, 100142, China.
FAU - Liu, Bojun
AU  - Liu B
AD  - Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, 
      Capital Medical University, Beijing, 100069, China.
FAU - Zou, Yinghua
AU  - Zou Y
AD  - Department of Interventional Radiology and Vascular Surgery, First Hospital, 
      Peking University, Beijing, 100034, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20211020
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
RN  - 25X51I8RD4 (Niacinamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Carcinoma, Hepatocellular/therapy
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Niacinamide
MH  - Phenylurea Compounds
MH  - Prospective Studies
MH  - Pyridines
MH  - Retrospective Studies
PMC - PMC8529854
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Regorafenib
OT  - Survival
OT  - Transarterial chemoembolization
OT  - Unresectable
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/22 06:00
MHDA- 2021/10/27 06:00
PMCR- 2021/10/20
CRDT- 2021/10/21 05:29
PHST- 2021/02/05 00:00 [received]
PHST- 2021/10/07 00:00 [accepted]
PHST- 2021/10/21 05:29 [entrez]
PHST- 2021/10/22 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2021/10/20 00:00 [pmc-release]
AID - 10.1186/s12876-021-01967-3 [pii]
AID - 1967 [pii]
AID - 10.1186/s12876-021-01967-3 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2021 Oct 20;21(1):393. doi: 10.1186/s12876-021-01967-3.